Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Mersana Therapeutics

Explore full profile

Platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives

Cambridge, United StatesFounded 2005Biotech & Life Sciences
Valuation $145M Market cap · 2026
Revenue $40M Latest reported FY

About Mersana Therapeutics

Mersana Therapeutics is a biopharmaceutical company focused on discovering and developing innovative antibody-drug conjugates (ADCs) to treat cancer. The company leverages its proprietary technology platforms, Dolasynthen and Immunosynthen, to create a robust pipeline of ADCs designed to target and destroy cancer cells while sparing healthy tissue. Mersana operates in the oncology market, serving patients and healthcare providers who seek advanced treatment options for various types of cancer. The company's business model involves research and development, clinical trials, and partnerships with other pharmaceutical companies to bring its ADCs to market. Revenue is generated through public offerings, partnerships, and potential future sales of approved therapies. Mersana's multiprong strategy includes both cytotoxic and immunostimulatory ADCs, aiming to provide comprehensive solutions for cancer treatment.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2005
Headquarters
Cambridge, United States
Listing
IPO 2017
Sector
Biotech & Life Sciences
Power Law
Colt$25–100M revenue

Investors

16 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

  • ProQuest Investments
  • F-Prime
  • Harris & Harris Group
  • Rho Capital Partners
  • NEA
  • Pfizer Ventures
  • Pfizer
  • Rock Spring Ventures

Series B and later8 investors entered at this stage

Team profiled 22 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States95.8%
🇵🇰 Pakistan2.1%
🇮🇳 India2.1%
3 countries shown
Web traffic by country
760 monthly visits
across markets
🇺🇸 United States105.3%
Top 1 markets shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Mersana Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Mersana Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.